The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Author: Ackler Scott   Mitten Michael   Foster Kelly   Oleksijew Anatol   Refici Marion   Tahir Stephen   Xiao Yu   Tse Christin   Frost David   Fesik Stephen   Rosenberg Saul   Elmore Steven   Shoemaker Alexander  

Publisher: Springer Publishing Company

ISSN: 0344-5704

Source: Cancer Chemotherapy and Pharmacology, Vol.66, Iss.5, 2010-10, pp. : 869-880

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next